Abstract: This invention relates to human and murine HPR1 and human and murine HPR2 polypeptides, new members of the hematopoietin receptor polypeptide family; to methods of making such HPR1 and HPR2 polypeptides; to non-human mammals in which the endogenous genomic sequences encoding HPR1 and/or HPR2 polypeptides have been partially or completely inactivated; to methods of using HPR1 or HPR2 polypeptides to identify compounds that alter HPR1 or HPR2 polypeptide activities; and to methods of preparing medicaments for and/or treating conditions associated with hematopoietin receptor function.

Abstract: This invention relates to IMX129840 cytokines, including new mammalian cytokine polypeptides; to methods of making such polypeptides; to methods of using them to treat conditions and diseases involving proliferation and/or differentiation of cells from pluripotent stem cell precursors; and to methods of identifying compounds that alter IMX129840 cytokine polypeptide activities.

Abstract: Provided is a new disintegrin polypeptide, methods of making such polypeptides, and methods of using them to treat disintegrin-associated disorders and conditions and to identify agents that modulate Metalloproteinase-Disintegrin polypeptide activities.

Abstract: This invention relates to IMX7189 cytokines and to new members of the human cytokine polypeptide family, methods of making such polypeptides, and to methods of using them to treat conditions and diseases involving proliferation and/or differentiation of cells from pluripotent stem cell precursors, and to identify compounds that alter cytokine polypeptide activities.

Abstract: A novel polypeptide functions as the ? chain of an oncostatin M receptor and is thus designated OSM-R?. Heterodimeric receptor proteins comprising OSM-R? and gp130 bind oncostatin M and find use in inhibiting biological activities mediated by oncostatin M.

Abstract: This invention relates to TMEM7 and TMEM7-related cytokines and to new members of the human cytokine polypeptide family, to methods of making such polypeptides, to methods of using them to treat conditions and diseases involving proliferation and/or differentiation of cells from pluripotent stem cell precursors, and to methods of using them to identify compounds that alter cytokine polypeptide activities.

Abstract: Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.

Abstract: DNA encoding H14 polypeptides and methods for using the encoded polypeptides are disclosed.

Abstract: A novel polypeptide functions as the &bgr; chain of an oncostatin M receptor and is thus designated OSM-R&bgr;. Heterodimeric receptor proteins comprising OSM-R&bgr; and gp130 bind oncostatin M and find use in inhibiting biological activities mediated by oncostatin M.

Abstract: Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.

Abstract: DNA encoding H14 polypeptides and methods for using the encoded polypeptides are disclosed.

Abstract: A novel polypeptide functions as the &bgr; chain of an oncostatin M receptor and is thus designated OSM-R&bgr;. Heterodimeric receptor proteins comprising OSM-R&bgr; and gp130 bind oncostatin M and find use in inhibiting biological activities mediated by oncostatin M.

Abstract: Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.

Abstract: A novel polypeptide functions as the .beta. chain of an oncostatin M receptor and is thus designated OSM-R.beta.. Heterodimeric receptor proteins comprising OSM-R.beta. and gp130 bind oncostatin M and find use in inhibiting biological activities mediated by oncostatin M.

Abstract: A novel polypeptide functions as the .beta. chain of an oncostatin M receptor and is thus designated OSM-R.beta.. Heterodimeric receptor proteins comprising OSM-R.beta. and gp130 bind oncostatin M and find use in inhibiting biological activities mediated by oncostatin M.

Abstract: A novel polypeptide functions as the .beta. chain of an oncostatin M receptor and is thus designated OSM-R.beta.. Heterodimeric receptor proteins comprising OSM-R.beta. and gp130 bind oncostatin M and find use in inhibiting biological activities mediated by oncostatin M.

Abstract: Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.

Abstract: Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.

Abstract: A novel polypeptide functions as the .beta. chain of an oncostatin M receptor and is thus designated OSM-R.beta.. Heterodimeric receptor proteins comprising OSM-R.beta. and gp130 bind oncostatin M and find use in inhibiting biological activities mediated by oncostatin M.

Abstract: Mammalian Interleukin-4 receptor proteins find use in inhibiting biological activities of IL-4. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.